Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome

Oestrogen receptor status cannot be used to select tumours for evaluation of HER‐2 status, and oestrogen and progesterone receptor positivity does not preclude a positive HER‐1 status, but there is a higher proportion of ERp negative tumours associated with Her‐2 positivity, however, more than 20% of HER-2 positive tumours show moderate or strong staining for ERp.

Abstract

Oestrogen receptor status cannot be used to select tumours for evaluation of HER-2 status, and oestrogen and progesterone receptor positivity does not preclude a positive HER-2 status. There is a higher proportion of ERp negative tumours associated with HER-2 positivity, however, more than 20% of HER-2 positive tumours show moderate or strong staining for ERp. HER-2 positive patients in this study did not show an adverse BCSS with tamoxifen treatment unlike some previous studies.